Abstract Body

Background: Antiretroviral therapy (ART) is thought to reduce mortality from active TB. We investigate the extent to which the increasing availability of ART predicts reductions in national TB mortality in countries with high dual HIV-TB burden.

Methods: We analyzed annual TB mortality rates in the 41 countries that the World Health Organization (WHO) defines as high HIV-TB burden, between 1996 and 2011. We analyzed two TB mortality outcomes: (1) TB death notifications reported by national TB control programs, adjusted for TB case detection rates, and (2) WHO estimates. National Coverage with ART, the percentage of treatment-eligible HIV+ population on ART, was obtained from UNAIDS. Panel linear regressions with country fixed effects tested the relationship of TB mortality to ART coverage scale-up, controlling for time-varying HIV prevalence (5-year lagged), coverage of TB interventions, gross domestic product per capita, health spending from domestic sources, and urbanization.

Results: Across multiple model specifications and lags between ART coverage and TB mortality, we consistently observed that increasing ART coverage was followed by reduced TB mortality. Using death notifications and a 2-year lag between ART scale-up and TB mortality, we find that a 1% increase in ART coverage was associated with a 0.9% faster decline in TB deaths (p=0.002). Using WHO death estimates as outcome, a 1% increase in ART was followed by 1.1% reduced TB deaths (p<0.001). TB mortality was higher at higher HIV prevalence (p<0.001), but not related to coverage of isoniazid preventive therapy, cotrimoxazole preventive therapy, or other covariates.

Conclusions: This econometric analysis confirms the assumed beneficial impact of between ART scale up on subsequent reductions in population-level TB mortality. However, the estimated effect size was smaller than typically assumed in global impact models.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V